Adial Pharmaceuticals Inc
Research Adial Pharmaceuticals Inc (ADIL) on Bullrun: market cap USD 8.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADIL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 8.78M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.02M
- Free cash flow-USD 6.52M
Valuation Snapshot
latest market cap is USD 8.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 7.98M | -USD 6.49M | n/a | -11.93 | USD 5.88M | n/a | USD 5.28M |
| FY2024 | USD 0 | -USD 13.20M | -USD 6.92M | n/a | -68.01 | USD 3.75M | n/a | USD 4.07M |
| FY2023 | USD 0 | -USD 5.12M | -USD 6.81M | n/a | -3.6 | USD 2.83M | USD 193.80K | USD 4.08M |
| FY2022 | n/a | -USD 12.73M | n/a | n/a | -12.71 | USD 4.00M | USD 207.38K | USD 3.28M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 8.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 6.11M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.54M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.26M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.91M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 56.53M | n/a | n/a | n/a |
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adial Pharmaceuticals Inc's market cap?
Adial Pharmaceuticals Inc's market capitalization is USD 8.78M.
What does Adial Pharmaceuticals Inc do?
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.